Document Detail

FDA LABA warning: is there anything new here?
MedLine Citation:
PMID:  20485319     Owner:  NLM     Status:  MEDLINE    
The FDA advisory on long-acting beta-agonists (LABAs) is not based on new data but on ongoing safety concerns about this class of medication. Not to be ignored are the potential safety risks of short-acting beta-agonists (SABAs).
S T Weiss
Related Documents :
18018439 - Benign paroxysmal positional vertigo in an airline pilot.
20485319 - Fda laba warning: is there anything new here?
9553329 - Clinical application of the new civil airman vision standards and certification procedu...
24552859 - Direct acting inhibitors of ammoniagenesis: a role in post-tips encephalopathy?
15182749 - The relationship of workers' compensation to the americans with disabilities act and fa...
23431859 - When is the sterilisation of an intellectually disabled child "therapeutic"? a practica...
972069 - Tetrazolium salts: a consumer's guide.
16799349 - Bispectral index and spectral entropy in neuroanesthesia.
20495259 - Bless me reader for i have sinned: physicians and confessional writing.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  87     ISSN:  1532-6535     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-20     Completed Date:  2010-06-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  638-9     Citation Subset:  AIM; IM    
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Adrenergic beta-Agonists / administration & dosage,  adverse effects*,  therapeutic use
Asthma / drug therapy
Delayed-Action Preparations
Drug Labeling*
Glucocorticoids / administration & dosage,  adverse effects,  therapeutic use
Practice Guidelines as Topic
United States
United States Food and Drug Administration
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Delayed-Action Preparations; 0/Glucocorticoids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dealing with the evidence dilemma in genomics and personalized medicine.
Next Document:  Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?